BioLineRx (NASDAQ:BLRX) Shares Cross Above 200-Day Moving Average – Should You Sell?

BioLineRx Ltd. (NASDAQ:BLRX) shares crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $3.82 and traded as high as $4.34. BioLineRx shares last traded at $4.22, with a volume of 58,051 shares trading hands.

Wall Street Analysts Forecast Growth

BLRX has been the topic of a number of research reports. Wall Street Zen upgraded BioLineRx to a “sell” rating in a research note on Saturday, July 12th. Weiss Ratings reissued a “sell (e+)” rating on shares of BioLineRx in a research report on Saturday, September 27th. Finally, HC Wainwright restated a “buy” rating on shares of BioLineRx in a research note on Tuesday, June 17th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $26.00.

BioLineRx Trading Up 5.5%

The company has a market capitalization of $17.98 million, a P/E ratio of -0.48 and a beta of 1.25. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.87 and a current ratio of 2.06. The stock has a fifty day moving average of $3.81 and a 200 day moving average of $3.82.

BioLineRx (NASDAQ:BLRX) last issued its quarterly earnings results on Thursday, August 14th. The biotechnology company reported ($1.00) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.65). BioLineRx had a negative return on equity of 49.74% and a negative net margin of 45.34%.The company had revenue of $0.30 million during the quarter, compared to analysts’ expectations of $0.66 million. As a group, equities research analysts anticipate that BioLineRx Ltd. will post -5.8 EPS for the current fiscal year.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.